Answer
During Rezolsta treatment, increased AST/ALT monitoring should be considered for patients with underlying chronic hepatitis, cirrhosis, or elevated transaminases before treatment, especially during the first several months.
Sources for this answer
- REZOLSTA 800 mg/150 mg film coated tabletsJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.4 Special warnings and precautions for use · Version 20Document updated
Sources checked